Whitmarsh Tristan, Treece Graham M, Gee Andrew H, Poole Kenneth E S
University of Cambridge, Department of Engineering, Trumpington Street, Cambridge, CB2 1PZ, United Kingdom.
University of Cambridge, Department of Medicine, Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom.
PLoS One. 2016 Feb 9;11(2):e0147722. doi: 10.1371/journal.pone.0147722. eCollection 2016.
Teriparatide (TPTD) is an anabolic agent indicated for the treatment of severely osteoporotic patients who are at high risk of fragility fractures. The originally approved duration of TPTD treatment in several regions, including Europe, was 18 months. However, studies of areal bone mineral density (aBMD) showed additional benefit when treatment is continued beyond 18 months, and the drug is currently licenced for 24 months. Improvements in cortical structure at the proximal femur have already been shown in patients given TPTD for 24 months using quantitative computed tomography (QCT). Here, we investigate whether cortical and endocortical trabecular changes differ between an 18- and 24-month treatment.
Since an 18- versus 24-month TPTD study using QCT has not been conducted, we studied combined QCT data from four previous clinical trials. Combined femoral QCT data from three 18-month TPTD studies ('18-month group') were compared with data from a fourth 24-month trial ('24-month group'). Cortical parameters were measured over the entire proximal femur which allowed for a comparison of the mean changes as well as a visual comparison of the colour maps of changes after 18 and 24 months TPTD.
For both the combined 18-month group and the 24-month group, overall cortical thickness and endocortical trabecular density increased, while overall cortical bone mineral density decreased. While the changes in the 24-month group were of greater magnitude compared to the 18-month group, the differences were only significant for the endocortical trabecular density (ECTD), corrected for age, weight, femoral neck T-score, total hip T-score and the baseline mean ECTD.
Although the combination of data from different clinical trials is not optimal, these data support the concept that the duration of TPTD in the 18-24 month phase is of clinical relevance when considering improvement in hip structure.
特立帕肽(TPTD)是一种促合成药物,用于治疗有脆性骨折高风险的严重骨质疏松患者。在包括欧洲在内的几个地区,最初批准的TPTD治疗疗程为18个月。然而,关于面骨矿物质密度(aBMD)的研究表明,治疗持续超过18个月会有额外益处,目前该药物获批的疗程为24个月。使用定量计算机断层扫描(QCT)对接受TPTD治疗24个月的患者进行的研究已显示股骨近端皮质结构有所改善。在此,我们研究18个月和24个月治疗在皮质和骨内膜小梁变化方面是否存在差异。
由于尚未开展使用QCT的18个月与24个月TPTD研究,我们研究了来自之前四项临床试验的综合QCT数据。将三项18个月TPTD研究(“18个月组”)的股骨QCT综合数据与第四项24个月试验(“24个月组”)的数据进行比较。在整个股骨近端测量皮质参数,这使得能够比较平均变化以及对TPTD治疗18个月和24个月后的变化彩色图进行视觉比较。
对于综合的18个月组和24个月组,总体皮质厚度和骨内膜小梁密度均增加,而总体皮质骨矿物质密度降低。虽然24个月组的变化幅度比18个月组更大,但差异仅在内膜小梁密度(ECTD)方面具有统计学意义,该差异经年龄、体重、股骨颈T值、全髋T值和基线平均ECTD校正。
尽管来自不同临床试验的数据组合并非最佳,但这些数据支持这样的概念,即在考虑髋部结构改善时,18 - 24个月阶段的TPTD疗程具有临床意义。